Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).
We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity relationships of 4 are described, and are also reconciled with those from the related 2-phenylsulfonylmethyl series.
Research and Development, Bristol-Myers Squibb Company, Route 206 & Provinceline Road, Princeton, NJ 08543-4000, United States.
Michael G
MG
Yang
Zili
Z
Xiao
Qing
Q
Shi
Robert J
RJ
Cherney
Andrew J
AJ
Tebben
George V
GV
De Lucca
Joseph B
JB
Santella
Ruowei
R
Mo
Mary Ellen
ME
Cvijic
Qihong
Q
Zhao
Joel C
JC
Barrish
Percy H
PH
Carter
D000577:Amides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D062365:Aminobenzoates / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D003500:Cyclization; D006801:Humans; D020128:Inhibitory Concentration 50; D051379:Mice; D008861:Microsomes / Q000201:enzymology; D008958:Models, Molecular; D015394:Molecular Structure; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D054390:Receptors, CCR2 / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013455:Sulfur / Q000737:chemistry* / Q000494:pharmacology
D000577:Amides; D062365:Aminobenzoates; D054390:Receptors, CCR2; D013455:Sulfur